SCHEMBL5636909

SCHEMBL5636909

N#CC(=Cc1c[nH]c2ccc([N+](=O)[O-])cc12)S(=O)(=O)c1cccs1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
MEN1 O00255 5/20 0.48
KMT2A Q03164 5/20 0.48
POLB P06746 2/20 0.48
NPSR1 Q6W5P4 1/20 0.48
LMNA P02545 2/20 0.47
RRM1 P23921 1/20 0.44
TNFSF11 O14788 1/20 0.43
TNF P01375 1/20 0.43
RXFP3 Q9NSD7 1/20 0.39
PSMD14 O00487 1/20 0.37
GAA P10253 1/20 0.37
TLR9 Q9NR96 1/20 0.37
KDM4E B2RXH2 1/20 0.37
NQO2 P16083 1/20 0.37
GABRP O00591 1/20 0.37
GABRD O14764 1/20 0.37
GABRA1 P14867 1/20 0.37
GABRB1 P18505 1/20 0.37
GABRG2 P18507 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5636906 1.00 MAPT (0.48) MAPTMEN1KMT2APOLBNPSR1
SCHEMBL5635746 0.81 MAPT (0.49) MAPTMEN1KMT2APOLBNPSR1
SCHEMBL5635744 0.81 MAPT (0.49) MAPTMEN1KMT2APOLBNPSR1
SCHEMBL5636404 0.81 MAPT (0.55) MAPTMEN1KMT2APOLBNPSR1
SCHEMBL5636407 0.81 MAPT (0.55) MAPTMEN1KMT2APOLBNPSR1
SCHEMBL3246996 0.77 APP (0.56) MAPTMEN1KMT2APOLBRRM1
SCHEMBL5637625 0.76 MEN1 (0.45) MAPTMEN1KMT2APOLBNPSR1
SCHEMBL5637622 0.76 MEN1 (0.45) MAPTMEN1KMT2APOLBNPSR1
SCHEMBL5634720 0.75 RXFP3 (0.52) MAPTMEN1KMT2APOLBNPSR1
SCHEMBL5634721 0.75 RXFP3 (0.52) MAPTMEN1KMT2APOLBNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070010559-A1 Indole derivatives for use as chemical uncoupler NOVO NORDISK A/S (DK) 2007-01-11 US claimed
EP-1689710-A1 INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER NOVO NORDISK A/S (DK) 2006-08-16 EP claimed
WO-2005051908-A1 INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER NOVO NORDISK A/S (DK) 2005-06-09 WO claimed
US-20070010559-A1 Indole derivatives for use as chemical uncoupler NOVO NORDISK A/S (DK) 2007-01-11 US disclosed
EP-1689710-A1 INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER NOVO NORDISK A/S (DK) 2006-08-16 EP disclosed
WO-2005051908-A1 INDOLE DERIVATIVES FOR USE AS CHEMICAL UNCOUPLER NOVO NORDISK A/S (DK) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010559-A1 Indole derivatives for use as chemical uncoupler GPR119, IDO2, IDO1 MAPT 4316/4885MEN1 4192/4885KMT2A 1438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.